SEC Form 4 · accession 0002071959-26-000008
Caris Life Sciences, Inc. · CAI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian J Brille
Officer — See Remarks · Director
Period of report
Sep 17, 2026
Accepted (ET)
Sep 17, 2026 · 6:08 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002019410
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 17, 2026 | M | 400,000 | $2.44 | A | 630,303 | D | |
| Common StockF1 | Sep 17, 2026 | S | 400,000 | $30.3302 | D | 230,303 | D | |
| Common StockF2,F3 | holding | — | — | — | 500,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF4 | $2.44 | Sep 17, 2026 | M | 400,000 | D | — | Jan 14, 2028 | Common Stock | 400,000 | 1,600,000 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2100 to $30.5650, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
- F3By a family trust, with shares previously held in multiple family trusts consolidated into a single trust.
- F4The stock option is fully vested and exercisable.
Remarks
Vice Chairman and Executive Vice President